Biotech Values

[north40000]

Bloomberg note on FDA staff concerns:

http://www.bloomberg.com/news/2012-06-18/onyx-s-cancer-drug-s-risk-may-outweigh-benefit-fda-says.html

Not an optimistic forecast at present time. That AC hearing should be contentious.